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Natural killer (NK) cells can attack cells infected with
certain pathogens [1, 2] and kill transformed cells [3].
Moreover, NK cells regulate adaptive immune re-
sponses [4]. Of clinical relevance is their ability to
mediate in part the therapeutic activity of antibodies
against tumors [5]. Finally, NK cells can inﬂuence the
outcome of bone marrow transplantation. Recipient
NK cells can completely prevent engraftment [6],
whereas alloreactive donor NK cells can prevent graft
versus host reactions [7] and may exert graft versus
leukemia eﬀects [7]. For a long time considered as being
non-speciﬁc, the understanding of the molecular basis
for the NK cell’s discriminatory capacities has made
considerable progress. We will distinguish three distinct
recognition strategies used by NK cells to identify
diseased or distressed host cells. These diﬀerent recog-
nition strategies do not act separately but are rather
used in a cooperative fashion.
Recognition of ‘‘non-self’’ ligands
Natural killer cells detect pathogen-infected host cells by
directly recognizing pathogen-encoded molecules. For
instance, NK cells from certain mouse strains protect
from lethal MCMV (Mouse Cytomegalovirus) infection.
NK cells recognize the MCMV-encoded protein m157
on the surface of infected cells [8, 9]. The recognition of
this foreign protein is mediated by the Ly49H receptor
[10]. Interestingly, the NK-cell response selects MCMV
variants with mutant m157, which escape Ly49H rec-
ognition. If the early MCMV infection is counteracted
by NK cells, mutant viruses are subsequently controlled
by an adaptive immune response [11]. These ﬁndings
highlight the importance and the eﬃcacy of NK cells
during early MCMV infection. The human NKp46 and
NKp44 NK-cell activation receptors may also be in-
volved in pathogen recognition, as they were shown to
bind inﬂuenza virus haemagglutinin [12].
In addition to recognizing pathogen-infected host
cells, NK cells may have the capacity to directly recog-
nize and respond to pathogen components through Toll-
like receptors (TLRs) [13, 14].
Recognition of constitutively expressed ‘‘self’’ ligands
Besides the direct recognition of foreign protein or
pathogen components, NK cells are equipped to deter-
mine whether various endogenous self-proteins are
normally expressed. To this end, NK cells use a dual
receptor system. They express a whole array of receptors
that transmit activation signals upon interacting with a
potential target cell [15]. In this context, we use the term
‘‘activation’’ to indicate the triggering of NK-cell eﬀec-
tor functions such as cytolysis or the production of
cytokines. In general, activation receptors are speciﬁc
for incompletely deﬁned, but constitutively expressed
ligands on potential target cells. Under normal circum-
stances, NK-cell activation is counteracted by inhibitory
NK-cell receptors, which interact with MHC-I (major
histocompatibility complex class I) molecules on target
cells. A signiﬁcant number of inhibitory NK-cell recep-
tors, which are speciﬁc for non-MHC-I ligands, have
also been identiﬁed [16–19]. The importance of these
receptors and how the signals from non-MHC and
MHC-I-speciﬁc inhibitory receptors are integrated are
currently unclear.
Natural killer cell inhibition by MHC-I on target cells
enables NK cells to kill MHC-I loss variants. In this
case, NK cells fail to receive inhibitory signals such that
NK-cell activation can proceed unopposed. This type of
recognition has been termed ‘‘missing-self’’ recognition
[20]. Total or selective MHC-I loss or down-modulation
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is a frequent event during viral infections or transfor-
mation [21, 22]. It is thus thought that the recognition of
MHC-I loss by NK cells complements T-cell-mediated
immunity.
A special case of missing-self reactivity may be the
lysis of immature dendritic cells (DC). NK-cell activa-
tion upon the interaction with DC occurs mainly via
human NKp30. Mature DC are protected from lysis
since they express high levels of HLA-E, which inhibits
NK cells via the CD94/NKG2A receptor. In contrast,
HLA-E expression on immature DC is low, allowing
NK-cell-mediated lysis [23]. The interaction with DC
likely reﬂects an immunoregulatory function of NK
cells, which inﬂuences subsequent adaptive immune re-
sponses [24].
Recognition of ‘‘induced-self’’ ligands
In addition to activation receptors, which recognize
constitutively expressed ligands, NK cells also express
receptors, which are speciﬁc for ligands that can be in-
duced on host cells but that are not normally expressed.
The NKG2D receptor serves as a paradigm for this type
of recognition (for review see [25]). Ligands for
NKG2D, which include RAE, MULT1 and H60 pro-
teins in the mouse and MICA/B and RAET in humans,
are not normally expressed on host cells. Importantly,
such ligands can be induced upon various cellular insults
including stress [26], infection [27, 28] and transforma-
tion [29]. However, NKG2D ligands can also be induced
during the course of normal cellular activation and dif-
ferentiation [30]. Irrespectively, upon the interaction
with host cells expressing NKG2D ligand, NK cells re-
ceive additional activation signals. In this case, host cells
can be lysed even though they express MHC-I molecules
normally, thus the term ‘‘induced-self’’ recognition [31].
Interestingly, the majority of the transformed cell lines
commonly used in vitro constitutively express NKG2D
ligands. An important area for future research will thus
be to determine how these genes are regulated.
Besides NKG2D ligands, it has been noted before
that CD80 (B7–1) expression by target cells can override
NK-cell inhibition [32]. Moreover, antibody-dependent
cell mediated cytotoxicity (ADCC) can be considered to
belong to the same recognition category. NK cells can
recognize and kill antibody-coated target cells, using
FccRIII (CD16). Similar to NKG2D, ADCC can
override NK-cell inhibition and allow the lysis of MHC-
I-expressing target cells [33].
Thus, over the last years, NK-cell activation has
emerged as a complex and regulated process, which in-
volves a signiﬁcant number of distinct NK-cell recep-
tors. Even though complete knowledge of all the
relevant ligands is still lacking, it has become apparent
that certain activation receptors recognize inducible li-
gands. Moreover, there are activating NK-cell receptors,
such as human NKp44, that are themselves inducible via
the action of cytokines [34].
In contrast to this, our view of NK-cell inhibition has
remained relatively simple. NK-cell inhibition depended
on the presence of the MHC-I ligand on the target cell
and the presence of a speciﬁc inhibitory receptor on NK
cells. We have recently made observations, which chal-
lenge this simplistic view. In order to discuss these
ﬁndings and their implications, we will ﬁrst introduce
the experimental system we established over the past
years.
Inhibitory MHC-I receptors
The prototype inhibitory receptor for classical MHC-I
in mouse is Ly49A, a homodimeric C-type lectin-like
receptor. Ly49A is part of a multigene family with >20
members [35, 36], whereby diﬀerent mouse strains have
variable numbers of Ly49 genes and individual receptors
are polymorphic [37]. Ly49 receptors are tightly linked
in the so-called NK gene complex (NKC) on mouse
chromosome 6 [38].
Both inhibitory and activating Ly49 family members
have been found. The function of the latter is still
somewhat enigmatic, even though one activating Ly49,
Ly49H, recognizes MCMV m157, as discussed above.
The majority of the inhibitory receptors are speciﬁc for
classical MHC-I [39]. Importantly, Ly49 receptors may
be selective for certain MHC-I isotypes and may even
discriminate certain alleles of MHC-I molecules. For
instance, Ly49A inhibits mouse NK cells upon interac-
tion with H-2Dd (Dd) or Dk but not Db or H-2K on
target cells [40].
The Ly49A receptor is expressed by approximately
20% of NK cells, irrespective of whether a particular
mouse strain expresses a corresponding MHC-I ligand.
This suggests that Ly49 receptor expression is not di-
rected by MHC-I. Ly49 receptors are diﬀerentially ex-
pressed such that individual NK cells express a selection
of the available receptors. Thus, using a relatively small
number of receptors, NK cells generate a relatively
complex receptor repertoire.
So far, functional Ly49 proteins have not been found
in humans. Rather, human NK cells use a structurally
distinct family of Ig-like receptors, the so-called killer
inhibitory receptors (KIR) to recognize classical MHC-I
molecules [41]. Despite the structural diﬀerences, KIR
and Ly49 receptors mediate identical functions, are
similarly selective for some but not all MHC-I molecules
and are clonally distributed in a comparable fashion.
Cross-linking of inhibitory MHC-I receptors results
in the phosphorylation of a tyrosine residue, which is
central to the so-called ITIM (for immuno receptor
tyrosine-based inhibition motif: I/S/T/LxYxxL/V), lo-
cated in the cytoplasmic tail of the receptor. ITIM
phosphorylation results in the recruitment and activa-
tion of phosphatases including SHP-1 and SHP-2 [42].
In turn, phosphatase activity interrupts the action of
NK-cell activation pathways by dephosphorylating
essential signaling intermediates, such as Vav1 [43].
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Ly49A transgenic mice
In order to somewhat simplify the complex NK-cell
receptor repertoire, we generated Ly49A transgenic (Tg)
mice [44]. In these mice, all NK cells have at least one
inhibitory receptor in common. However, endogenous
Ly49 receptors are still expressed [45]. The transgenic
Ly49A conferred Dd-speciﬁc NK-cell inhibition and
prevented T-cell responses to allogeneic stimulator cells
when these expressed inhibitory MHC-I ligand. This has
provided formal evidence that Ly49A is an inhibitory
receptor and not just a co-receptor for another, un-
known receptor.
NK-cell inhibition is regulated by the MHC-I
of the NK cells
Unexpectedly, the capacity of Ly49A to inhibit NK cells
depends on the MHC-I background [46]. When NK cells
are derived from a mouse strain lacking a Ly49A ligand
such as C57BL/6 (B6)(H-2b), Ly49A very eﬃciently
inhibits the lysis of a Dd transfected tumor target cell. In
contrast, Ly49A NK cells from Dd transgenic B6 mice
were ineﬃcient at inhibiting the lysis of these same targets,
meaning that target cells were eﬃciently killed. Diﬀeren-
tial NK-cell inhibition was invoked since the lysis of the
parental (Dd-negative) tumor cells by the two NK-cell
populations was identical. Thus, while NK-cell activation
was near identical, NK-cell inhibition was very diﬀerent.
While NK-cell inhibition via Ly49A was inﬂuenced
by Dd expression, the above experiments did not resolve
whether Dd was required in the environment or on the
NK cells themselves. To address this issue, we used mice
with mosaic expression of Dd [47], in which Dd-
expressing cells co-exist with those lacking Dd. NK cells
from mosaic mice cannot kill target cells, which lack Dd,
due to some poorly understood tolerance mechanism
[47, 48]. However, when the Dd-expressing NK cells are
puriﬁed and cultured separately, they re-acquire the
ability to kill Dd-negative targets [48]. Interestingly,
Ly49A NK cells from mosaic mice, which expressed Dd,
had a low capacity to inhibit NK-cell function. In con-
trast, those lacking Dd had a high inhibitory capacity
[46]. Since both types of NK cells developed in the same
environment, it can be concluded that Dd expression by
the NK cells themselves determines Ly49A function.
Reduced NK-cell inhibition correlates with reduced
MHC-I binding
Since Ly49A function was regulated by the NK cell’s
MHC-I, we tested whether this was related to the ability
of Ly49A to bind MHC-I. To test this, we stained NK
cells with soluble, multimeric, ﬂuorochrome-labeled Dk,
the alternative Ly49A ligand. The presence of Dd on the
NK cells reduced the binding of an anti-Ly49A mAb
twofold. In contrast, Dk multimer binding was >10-fold
reduced. Thus, the capacity of Ly49A to bind soluble
MHC-I ligand was signiﬁcantly reduced when Ly49A
was co-expressed with Dd.
Similar to B- or T-cell receptors, Ly49A can
mediate the uptake of ligands from environmental
cells. While the physiological relevance of this phe-
nomenon for NK cells is uncertain, we used it to
determine the capacity of Ly49A to interact with Dd
expressed on a target cell. Indeed, the NK cell’s
capacity to acquire Dd via Ly49A was drastically re-
duced when Ly49A was co-expressed with Dd [49].
Thus, Ly49A shows a limited capacity to bind MHC-I
ligand on another cell when Ly49A is co-expressed
with its MHC-I ligand on the same cell.
Physical association of Ly49A and D d in cis
Three independent lines of evidence showed that a large
fraction of Ly49A receptors was physically associated
with Dd in the plane of the NK cell’s membrane [46].
First, capping of Ly49A on living cells resulted in the co-
capping of Dd but not of CD45. This suggested that
Ly49A and Dd were indeed associated on living cells.
Second, mild acid treatment was used to disrupt MHC-I
complexes on the surface of living cells. The treatment of
Dd-expressing NK cells with acid greatly improved the
binding of MHC-I multimer to Ly49A. This suggested
that Ly49A was masked by Dd on the surface of NK
cells. Finally, Dd but not Db or Kb co-immunoprecipi-
tated with Ly49A. Thus, Ly49A and Dd are physically
associated in the plane of the NK cell’s membrane.
Interestingly, the interaction in cis and trans showed the
same speciﬁcity for Dd. The association of Ly49A with
Dd in cis seems to mask the majority of Ly49A receptors
such that they are unavailable to interact with MHC-I
ligand in trans.
The site of Ly49A–D d interaction
The crystal structure of Ly49A-Dd complexes suggested
the existence of two distinct sites of interaction between
Ly49A and Dd [50]. On the one hand, Ly49A interacted
with amino and carboxy terminal residues of the a1 and
a2 helix, respectively (site 1). A second site was located
laterally, beneath the ﬂoor of the peptide-binding
groove, making contacts with residues of the a2, a3 and
b2m domains (site 2). Interestingly, site 2 is similar to the
binding site used by CD8 [51]. Subsequent site-directed
mutagenesis analysis demonstrated that site 2 was the
binding site used for Ly49A trans interaction, which
mediates NK-cell inhibition [52, 53].
It was thus important to determine whether the
binding site used for cis association was site 1 or site 2 or
even an unknown third binding site. The analysis of a
series of point mutations in Dd as well as the use of
species-speciﬁc diﬀerences in b2m revealed that cis and
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trans interactions use the same binding sites, i.e. site 2
[46]. Thus, cis and trans interactions show exactly the
same speciﬁcity.
Since binding site 2 is not symmetric, it is not
immediately obvious how Ly49A can recognize Dd in
trans or cis using a single binding site. Moreover, a
Ly49A homodimer interacts with a single Dd molecule
[50], suggesting that simultaneous binding in cis and
trans is excluded. However, there is no structural
information available regarding the Ly49A stalk (the
connector between the plasma membrane and the car-
bohydrate recognition domain (CRD), which mediates
MHC-I binding). We thus hypothesize that Ly49A
adopts an extended conformation to recognize Dd in
trans, whereas a back-folded conformation would be
required to interact with Dd in cis. The above model
implies that considerable ﬂexibility of the Ly49A stalk is
required to enable both cis and trans interactions by
Ly49A. This model has some resemblance to the distinct
conformational states adopted by active and resting in-
tegrins [54].
Implications for NK-cell function
Why should most of the Ly49A receptors be bound to
Dd in cis and thus be unavailable to inhibit NK-cell
function upon the interaction with a Dd-expressing tar-
get cell? First, it is important to note that our functional
evidence suggests that Ly49A, which is bound in cis,
does not constitutively transmit inhibitory signals [46].
Thus, only the Ly49A receptors, which are available for
trans interaction, seem to participate in NK-cell inhibi-
tion upon target cell interaction. Second, the small
amount of accessible Ly49A on Dd-expressing NK cells
is apparently suﬃcient to inhibit NK cells in response to
normal, Dd-expressing target cells [55] and thus suﬃcient
to ensure self-tolerance. Since the number of accessible
Ly49A molecules is small, a relatively minor reduction
in Dd expression on target cells will be suﬃcient to
abrogate NK-cell inhibition. Alternatively, minor in-
creases in NK-cell activation, e.g. upon the expression of
NKG2D ligands on target cells, are suﬃcient to over-
come NK-cell inhibition [46].
Concluding remarks
Natural killer cell function is negatively regulated by
inhibitory receptors interacting with MHC-I molecules
expressed on target cells. We have found that the
inhibitory Ly49A NK-cell receptor not only binds to its
Dd ligand expressed on potential target cells (i.e. in
trans), but is constitutively associated with Dd in cis
(i.e. on the same cell). Cis association seems to limit the
number of Ly49A receptors available for binding Dd on
target cells. In this way, cis association limits NK-cell
inhibition via Ly49A. Consequently, cis association
lowers the threshold at which NK-cell activation ex-
ceeds NK-cell inhibition. This allows an optimal dis-
crimination of healthy from distressed or diseased host
cells. Thus, the NK cell’s own MHC-I plays an
important role in the regulation of the function of
murine NK cells.
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